#hashtagacquistioncellularday tradingfinancialiliadmergersprintstock markett-mobiletechnologyvideo

Sprint calls off merger with T-Mobile, ILiad makes surprise bid for 15 billion (Video)

August 6, 2014 — by feedmeister0

French Telecom company has made a 15 billion dollar bid for T-Mobile.  According to news, a deal with Iliad would make T-Mobile worth .50 cent more a share than a deal with Sprint, and would offer a lot more room to grow.  The deal with Iliad would also give them around a 57% stake of the company. 

 I posted 2 videos here:
(1) The 1st is a video from France24 talking more about Iliad’s proposed deal.
(2) The 2nd is CNBC having Berenberg analyst Wassil El Hebil’s opinion on the Iliad bid for T-Mobile. 

#hashtagaccidentamazingawesomebusinesscrashday tradingfinancialinventionipoisraelmobileyesciencestock markettechnologyvideoworld record

Mobileye raises $890 Million as largest Israeli IPO in U.S. History (Video)

August 2, 2014 — by feedmeister0

Mobileye came in Large on the New York Stock Exchange on friday morning opening up at $36 a share.  Mobileye opened $11 dollars higher than it’s original calculated share price of $25.  They reached a high of 39.40.  The end of day closing price was $37.00.

Mobileye for most that don’t know is an advanced technology company that develops vision-based Advanced Driver Assistance Systems for automobiles etc. This technology offers advanced Visual and auditory warnings of impending collisions.  

I have attached three videos here: 
(1) The 1st video describes in more detail about who Mobileye is, and what they actually do.  
(2) The 2nd is a video of a 2014 Tesla model S equipped with the Mobileye collision aviodance system.  
(3) The 3rd video is what bloomberg had to say about Mobileye’s IPO opening on friday.

acquisitionday tradingfinancialglaxosmithklinemedicinepernixpharmaceuticalstock market

PERNIX signs agreement to acquire TREXIMET Tablets for Migraine from GlaxoSmithKline

May 14, 2014 — by feedmeister0

Pernix Therapeutics Holdings, today announced that it has signed an agreement with GlaxoSmithKline to acquire the U.S rights to Treximet for the acute treatment of migraine attacks with or without aura in adults. The acquistion adds immediate revenues and earnings for Pernix.  The net sales for Treximex for the full year of 2013 was 78.7 million.  This deal is expected to double Pernix’s revenue for 2014.  Pernix will make an upfront payment to GSK of $250 million for the U.S rights to Treximet.  Here is the full story on Pernix’s website.

acquisitionday tradingfinancialfoodstock market

Pinnacle Foods Signs Definitive Agreement for Sale of Company to Hillshire Brands

May 12, 2014 — by feedmeister0

Pinnacle Foods announced today that it has entered into a definitive agreement for the sale of the Company to Hillshire Brands in a transaction to include cash and Hillshire common stock.  Hillshire will acquire all outstanding shares of Pinnacle Foods.  Pinnacle stockholders will receive $18.00 in cash for each share held, along with Hillshire common stock at a fixed exchange ratio of 0.50 Hillshire shares for each Pinnacle share.  The transaction represents an implied premium of approximately 80% since Pinnacle’s March 28, 2013 IPO.  Here is the news release on Pinnacle’s website.

day tradingfdafinancialpharmaceuticalstock market

Prima BioMed’s CVac Granted Fast Track Designation by FDA (NEWS)

May 9, 2014 — by feedmeister0

Prima BioMed  is pleased to announce today that the United States Food and Drug Administration granted Fast Track Designation to the CVac clinical development program at Prima. This program is intended to improve overall survival in patients with relapsed platinum-sensitive epithelial ovarian cancer who enter a second complete remission. Prima will work closely with the FDA in accelerating its development program for CVac to potentially bring this treatment option to patients in the U.S.  Here is the full PDF on Prima’s website.

alibabachinaday tradingfinancialinternetiponewsstock markettechnologyvideo

‘Alibaba’ Possibly Largest I.P.O. Ever (Video)

May 7, 2014 — by feedmeister0

Alibaba, China’s largest e-commerce company, is on the verge of going public in New York. When it does, it could be one the largest I.P.O.s in the United States ever.  Yahoo is selling 208 million shares, or about 40 percent of it’s stake in the Chinese Internet Behemoth ‘Alibaba.’ This could generate as much as 10 billion for yahoo.  If Yahoo sells all of their shares, this said could double their cash assets.
~please checkout the cool ads before you go, thanks for visiting~

acquisitionday tradingfinancialoffice depotstock market

Office Depot releases first financials since merger with Office Max

May 6, 2014 — by feedmeister0

The New Office Depot formed by the merger of Office Depot and OfficeMax back in November of 2013, today announced results for the first quarter ended March 29, 2014.  Office Depot announced Quarterly Sales of 4.3 billion, compared to sales of 2.7 billion in the same quarter of last year.  Gross Profit was 1 billion, compared to 660 million in the same quarter of last year.  Quarterly Net Loss was 108 million, compared to 7 million, mainly because of the merger expenses.  The first quarter 2014 operating loss included special charges totaling $151 million, which were comprised of $96 million in merger-related expenses, $41 million in non-cash IT-related impairment charges, $9 million in non-cash store impairment charges, and $5 million in International restructuring and other operating expenses.  Here is Office Depot’s SEC Filing.

day tradingfinancialmersnewspharmaceuticalstock marketvirus

Hemispherx Biopharma Announces Alferon N Effective Against MERS

May 5, 2014 — by feedmeister0

Hemispherx Biopharma just announced that one of its advanced stage biological products, AlferonĀ® N, significantly inhibited the replication of the MERS virus in vitro. MERS-CoV is a recently emerged human coronavirus responsible for the lethal pulmonary syndrome known as MERS.  Hemispherx Biopharma Recent testing in laboratories of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has revealed that AlferonĀ® N was inhibitory to MERS-CoV both when used before test cells were exposed to MERS-CoV, as well as after the cells were exposed to the deadly virus.  To read more check out the article on Hemispherx’s Website: